Rosiglitazone treatment reduces hippocampal neuronal damage possibly through alleviating oxidative stress in chronic cerebral hypoperfusion.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neurochemistry International

• Publication date

  2012-08-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.neuint.2012.05.011PMID 22609374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus

  2012cited by this paper
• Neuroprotective efficacy of the peroxisome proliferator-activated receptor-γ ligand in chronic cerebral hypoperfusion.

  2011cited by this paper
• Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats.

  2011cited by this paper
• Gypenosides improve cognitive impairment induced by chronic cerebral hypoperfusion in rats by suppressing oxidative stress and astrocytic activation

  2011cited by this paper
• PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.

  2008cited by this paper
• l-3-n-Butylphthalide Improves Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats

  2007cited by this paper
• Rosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.

  2007cited by this paper
• Pre-treatment and post-treatment with alpha-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion.

  2007influential reference
• Peroxisome Proliferator-activated Receptor γ Up-regulates the Bcl-2 Anti-apoptotic Protein in Neurons and Induces Mitochondrial Stabilization and Protection against Oxidative Stress and Apoptosis*

  2007cited by this paper
• Peroxisome proliferator‐activated receptor‐γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type‐2 diabetic rodents

  2006cited by this paper
• Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.

  2006cited by this paper
• Study of the oxidative stress in a rat model of chronic brain hypoperfusion.

  2005cited by this paper
• Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia

  2005cited by this paper
• Diazoxide and dimethyl sulphoxide prevent cerebral hypoperfusion-related learning dysfunction and brain damage after carotid artery occlusion.

  2004cited by this paper
• Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease

  2002cited by this paper

• Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective

  2024cites this paper
• Oxidative stress and chronic cerebral hypoperfusion: An overview from preclinical rodent models

  2024cites this paper
• Iron homeostasis imbalance and ferroptosis in brain diseases

  2023cites this paper
• Insight into the potential role of ferroptosis in neurodegenerative diseases

  2022cites this paper
• Ferroptosis and Its Multifaceted Roles in Cerebral Stroke

  2021cites this paper
• Cross Talk Between Ferroptosis and Cerebral Ischemia

  2020cites this paper
• Deficiency of Nrf2 exacerbates white matter damage and microglia/macrophage levels in a mouse model of vascular cognitive impairment

  2020cites this paper
• The Emerging Roles of Ferroptosis in Vascular Cognitive Impairment

  2019cites this paper
• Assessing the protective effect of rosiglitazone against electronic cigarette/tobacco smoke-induced blood–brain barrier impairment

  2019cites this paper
• Cerebrovascular and Neurological Disorders: Protective Role of NRF2

  2019cites this paper
• Anti-Diabetic Countermeasures Against Tobacco Smoke-Dependent Cerebrovascular Toxicity: Use and Effect of Rosiglitazone

  2019cites this paper
• Investigation of inflammatory and oxidative stress mechanisms in the disruption of white matter structure and function following chronic cerebral hypoperfusion

  2019cites this paper
• Rosiglitazone attenuates lipopolysaccharide-induced depressive-like behavior and cognitive deficits in mice

  2018cites this paper
• Astrocyte-specific overexpression of Nrf2 protects against optic tract damage and behavioural alterations in a mouse model of cerebral hypoperfusion

  2018cites this paper
• Molecular Mechanisms of Vascular Dementia: What Can Be Learned from Animal Models of Chronic Cerebral Hypoperfusion?

  2016cites this paper
• Antioxidant Status in Vascular Dementia

  2015cites this paper
• Pharmacological modulation of I(1)-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia.

  2014cites this paper
• Rosiglitazone Enhances Apolipoprotein M (Apom) Expression in Rat's Liver

  2014cites this paper
• Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion.

  2014influential citation
• PPARs: a potential target for a disease-modifying strategy in stroke.

  2013cites this paper